Intravenous Immunoglobulin (IVIg) Market Research Report Information Information By Type (IgD, IgG, IgE, IgA, IgM), By Application (Guillain–Barré Syndrome, Hypogammaglobulinemia, Specific Antibody Deficiency, Chronic Inflammatory Polyneuropathy, Inflammatory Myopathies, Myasthenia Gravis, Idiopathic Thrombocytopenic Purpura, Multifocal Motor Neuropathy), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2030

ID: MRFR/Pharma/2259-HCR | 80 Pages | Author: Kinjoll Dey | June 2023

Table of Content

1. Report Prologue

2. Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

2.3 Market Structure

2.4. Market Segmentation

3. Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Mega Trends

4.5 Macroeconomic Indicators

5. Market Factor Analysis

5.1 Value Chain Analysis

5.2 Porters Five Forces

5.3 Demand & Supply: Gap Analysis

5.4 Pricing Analysis

5.5 Investment Opportunity Analysis

5.6 Merger and Acquisition Landscape

5.7 Upcoming trends

5.7.1 Market trends

5.7.2 Technological trends

5.7.3 Insurance & Regulations

5.7.4 Others

6. Global Intravenous Immunoglobulin (IVIg) Market by Type

6.1 IgA

6.1.1 IgA1

6.1.2 IgA2

6.2 IgD

6.3 IgE

6.4 IgG

6.5 IgM

7. Global Intravenous Immunoglobulin (IVIg) Market by Application

7.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

7.1.1 Progressive

7.1.2 Recurrent

7.1.3 Monophasic

7.2 Hypogammaglobulinemia

7.2.1 AGM1

7.2.2 AGM2

7.2.3 AGM3

7.2.4 AGM4

7.2.5 AGM5

7.2.6 AGM6

7.3 Multifocal Motor Neuropathy

7.4 Immunodeficiency diseases

7.4.1 X-linked agammaglobulinemia (XLA)

7.4.2 Common variable immunodeficiency (CVID)

7.2.4 Severe combined immunodeficiency

7.5 Primary Humoral Immunodeficiency

7.5.1 B cell (antibody) deficiencie

7.5.2 T cell deficiencies

7.5.3 Combination BT cell deficiencies

7.5.4 Defective phagocytes

7.5.5 Complement deficiencies

7.5.6 Unknown (idiopathic)

7.6 Myasthenia Gravis

7.6.1 Generalized myasthenia gravis

7.6.2 Ocular myasthenia gravis

7.6.3 Congenital myasthenia gravis

7.6.4 Transient neonatal myasthenia gravis

7.7 Guillain-Barre syndrome

7.7.1 Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)

7.7.2 Miller Fisher syndrome (MFS)

7.7.3 Acute motor axonal neuropathy (AMAN)

7.7.4 Acute motor-sensory axonal neuropathy (AMSAN)

7.8 Kawasaki disease

7.9 ITP

7.9.1 Acute

7.9.2 Chronic

7.9 Others

8. Global Intravenous Immunoglobulin (IVIg) Market by Region

8.1 Introduction

8.2 America

8.2.1 North America

8.2.1.1 The US

8.2.1.2 Canada

8.2.2 South America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.3 Spain

8.3.1.5 UK

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia

8.4.1 China

8.4.2 India

8.4.3 Japan

8.4.4 South Korea

8.4.5 Rest of Asia

8.5 Pacific

8.6 Middle East and Africa

8.6.1 UAE

8.6.2 Saudi Arabia

8.6.3 Egypt

8.6.4 Rest of Middle East and Africa

9 Conclusion

9.1 Key findings

9.1.1 From CEO’s viewpoint

9.1.2 Unmet needs of the market

9.2 Key companies to watch

9.3 Prediction of medical robots industry

10 Appendix

Market Segmentation

Intravenous Immunoglobulin (IVIg) Type Outlook (USD Billion, 2019-2030)

Intravenous Immunoglobulin (IVIg) Application Outlook (USD Billion, 2019-2030)

Guillain–Barré Syndrome

Hypogammaglobulinemia

Specific Antibody Deficiency

Chronic Inflammatory Polyneuropathy

Inflammatory Myopathies

Myasthenia Gravis

Idiopathic Thrombocytopenic Purpura

Multifocal Motor Neuropathy

Intravenous Immunoglobulin (IVIg) Regional Outlook (USD Billion, 2019-2030)

North America Outlook (USD Billion, 2019-2030)
- North America Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- North America Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- US Outlook (USD Billion, 2019-2030)
- US Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- US Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- CANADA Outlook (USD Billion, 2019-2030)
- CANADA Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- CANADA Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy

Europe Outlook (USD Billion, 2019-2030)
- Europe Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Europe Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- Germany Outlook (USD Billion, 2019-2030)
- Germany Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Germany Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- France Outlook (USD Billion, 2019-2030)
- France Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- France Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- UK Outlook (USD Billion, 2019-2030)
- UK Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- UK Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- ITALY Outlook (USD Billion, 2019-2030)
- ITALY Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- ITALY Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- Spain Outlook (USD Billion, 2019-2030)
- Spain Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Spain Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- Rest of Europe Outlook (USD Billion, 2019-2030)
- Rest of Europe Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Rest of Europe Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy

Asia Pacific Outlook (USD Billion, 2019-2030)
- Asia Pacific Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Asia Pacific Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- China Outlook (USD Billion, 2019-2030)
- China Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- China Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- Japan Outlook (USD Billion, 2019-2030)
- Japan Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Japan Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- India Outlook (USD Billion, 2019-2030)
- India Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- India Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- Australia Outlook (USD Billion, 2019-2030)
- Australia Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Australia Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- Rest of Asia Pacific Outlook (USD Billion, 2019-2030)
- Rest of Asia Pacific Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Rest of Asia Pacific Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy

Rest of World Outlook (USD Billion, 2019-2030)
- Rest of World Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Rest of World Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- Middle East Outlook (USD Billion, 2019-2030)
- Middle East Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Middle East Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- Africa Outlook (USD Billion, 2019-2030)
- Africa Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Africa Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy
- Latin America Outlook (USD Billion, 2019-2030)
- Latin America Intravenous Immunoglobulin (IVIg) by Type
  - IgD
  - IgG
  - IgE
  - IgA
  - IgM
- Latin America Intravenous Immunoglobulin (IVIg) by Application
  - Guillain–Barré Syndrome
  - Hypogammaglobulinemia
  - Specific Antibody Deficiency
  - Chronic Inflammatory Polyneuropathy
  - Inflammatory Myopathies
  - Myasthenia Gravis
  - Idiopathic Thrombocytopenic Purpura
  - Multifocal Motor Neuropathy

Leading companies partner with us for data-driven Insights.

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Request Free Sample

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.

Ask for Customization

Related Reports

Pemphigus Vulgaris Market Research Report - Global Forecast till 2030

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report - Global Forecast...

Purpura Treatment Market Research Report- Global Forecast To 2030

Press Release

Intravenous Immunoglobulin (Ivig) Market Is Expected To Grow At Significant Growth Rate Of 7.50 %...